Research programme: lymphoma therapeutics - Janssen Biotech/Weill Cornell Medical College
Latest Information Update: 04 Jul 2014
At a glance
- Originator Janssen Biotech; Weill Cornell Medical College
- Mechanism of Action Protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Lymphoma
Most Recent Events
- 19 Jun 2014 Early research in Lymphoma in USA (unspecified route)